Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538966 | 0.87 | KMT2A (0.32) | KMT2AGPR139ALDH1A1MAPT | |
| SCHEMBL7544500 | 0.78 | MAPK1 (0.41) | KMT2AGPR139ALDH1A1 | |
| SCHEMBL1195324 | 0.77 | AKR1B1 (0.44) | CYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL20772213 | 0.77 | MAPT (0.36) | KMT2AHPGDSALKBH2ALDH1A1MAPT | |
| SCHEMBL3152998 | 0.75 | TSHR (0.39) | CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL5363164 | 0.75 | TRPA1 (0.39) | ALDH1A1 | |
| SCHEMBL7544520 | 0.73 | TDP1 (0.42) | KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL23532019 | 0.72 | TP53 (0.39) | KMT2ACYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL5267243 | 0.72 | ALKBH2 (0.53) | HPGDSALKBH2MAPT | |
| SCHEMBL7540410 | 0.72 | ATM (0.36) | KMT2AGPR139CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6468995-B1 | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-0667868-B1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-20010056089-A1 | Novel crystal of cephalosporin compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| US-20010007903-A1 | NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-12 | — | — | US | disclosed |
| EP-0780393-A1 | NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| CN-1116425-A | New cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-02-07 | — | — | CN | disclosed |
| EP-0667868-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995007283-A1 | NEW CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056089-A1 | Novel crystal of cephalosporin compound | CEP170, CXXC4, DAO | KMT2A 776/4885GPR139 3016/4885CYP1A2 2032/4885 |
| US-20010007903-A1 | NOVEL CRYSTAL OF CEPHALOSPORIN COMPOUND | CEP170, CXXC4, DAO | KMT2A 776/4885GPR139 3016/4885CYP1A2 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.